WuXi AppTec Co., Ltd.

HKSE 2359.HK

WuXi AppTec Co., Ltd. Inventory for the year ending December 31, 2023: USD 667.10 M

WuXi AppTec Co., Ltd. Inventory is USD 667.10 M for the year ending December 31, 2023, a -18.79% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.
  • WuXi AppTec Co., Ltd. Inventory for the year ending December 31, 2022 was USD 821.44 M, a -11.61% change year over year.
  • WuXi AppTec Co., Ltd. Inventory for the year ending December 31, 2021 was USD 929.33 M, a 125.85% change year over year.
  • WuXi AppTec Co., Ltd. Inventory for the year ending December 31, 2020 was USD 411.47 M, a 64.44% change year over year.
  • WuXi AppTec Co., Ltd. Inventory for the year ending December 31, 2019 was USD 250.22 M, a 80.68% change year over year.
Key data
Date Inventory Goodwill Total Assets Current Liabilities
Market news
Loading...
SV Wall Street
HKSE: 2359.HK

WuXi AppTec Co., Ltd.

CEO Dr. Ge Li Ph.D.
IPO Date Dec. 13, 2018
Location China
Headquarters 288 Fute Zhong Road
Employees 41,116
Sector Health Care
Industries
Description

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Similar companies

6185.HK

CanSino Biologics Inc.

USD 3.69

-0.71%

3759.HK

Pharmaron Beijing Co., Ltd.

USD 1.84

0.83%

6160.HK

BeiGene, Ltd.

USD 17.19

2.12%

1801.HK

Innovent Biologics, Inc.

USD 4.24

1.99%

2269.HK

WuXi Biologics (Cayman) Inc.

USD 2.37

1.19%

StockViz Staff

January 31, 2025

Any question? Send us an email